Pharma
Alexion Pharmaceuticals, Inc.
2
Articles
Primary Subject
Top Role
Mar 10, 2026
First Mention
Mar 12, 2026
Last Mention
2.42
Relevance Score
Coverage Timeline
March 2026
Biosimilar Adoption Rates: ABP 959’s Market Share Challenge to Soliris After 2025
Data
Primary Subject
Mar 12, 2026
Alexion’s Soliris (eculizumab) anchored the paroxysmal nocturnal hemoglobinuria (PNH) market with approximately $4 billion in global sales last year.
AstraZeneca Names New CFO as $16B in Annual Revenue Nears Patent Cliff: What Happens Next?
People
Mentioned
Mar 10, 2026
The outgoing CFO, well-known for measured capital allocation, steered the $39 billion Alexion acquisition.